5 Key Takeaways

• 1

  The AVONELLE-X trial demonstrated stable vision and anatomy in nAMD patients treated with faricimab over a 4-year period.

• 2

  Patients in the trial received fewer injections, averaging about 7 in the last two years, contrasting with historical declines in vision.

• 3

  Switching from aflibercept to faricimab resulted in 44% fewer patients with persistent retinal fluid by the end of year four.

• 4

  Over 60% of patients achieved a maximum treatment interval of 16 weeks, indicating the durability of faricimab.

• 5

  Faricimab maintained a clean safety profile, consistent with earlier studies, with no cases of occlusive vasculitis reported.